UPB — Upstream Bio Cashflow Statement
0.000.00%
- $450.45m
- -$20.00m
- $2.37m
Annual cashflow statement for Upstream Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -23.9 | -20.5 | -62.8 |
Depreciation | |||
Non-Cash Items | 1.43 | -13.3 | 1.67 |
Other Non-Cash Items | |||
Changes in Working Capital | 3.41 | -4.17 | 1.87 |
Change in Accounts Receivable | |||
Change in Prepaid Expenses | |||
Change in Other Assets | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Change in Other Liabilities | |||
Cash from Operating Activities | -19 | -37.9 | -59.2 |
Capital Expenditures | -0.082 | -0.144 | -0.511 |
Purchase of Fixed Assets | |||
Other Investing Cash Flow Items | 0 | -82.7 | -59 |
Sale/Maturity of Investment | |||
Purchase of Investments | |||
Cash from Investing Activities | -0.082 | -82.8 | -59.5 |
Financing Cash Flow Items | — | — | -3.9 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Cash from Financing Activities | 9.96 | 130 | 419 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | -9.14 | 8.78 | 300 |